Geoff Saunders retirement announcement

Geoff qualified as a Pharmacist in 1982 and has held a variety of NHS roles as an oncology pharmacist since then. His current role of Consultant Oncology Pharmacist at the Christie Hospital in Manchester combines clinical practice, leadership, education and research & evaluation. As an independent prescriber he works alongside colleagues in the Gynae medical oncology clinics facilitating the prescription of chemotherapy and supportive medication. Geoff was chair of BOPA from 2007 to 2009 and has had a positive influence on many pharmacists over the years with his strong leadership and clinical skills.

 

BOPA wishes former chair and BOPA fellow Geoff Saunders a very happy retirement!

Take Care Geoff, Oncology Pharmacy will miss you!

Latest News

By BOPA Research Committee on 25th April 2024

Survey: Pharmacogenomic Panel Testing in Cancer: UK Oncology Professionals

Please consider completing our BOPA member survey on the use of pharmacogenomic panel testing in people with solid tumours. Survey information I’m a pharmacist and pre-doctoral research fellow researching the…

Read article
By BOPA Research committee on 25th April 2024

NIHR Associate Principal Investigator (PI) Scheme is continuing to host Research Learning Lectures

The NIHR Associate Principal Investigator (PI) Scheme is continuing to host the Research Learning Lectures; a series of lectures for anyone in Health and Social Care interested in learning more about research.…

Read article
By BOPA on 16th April 2024

Abstract Submission for #BOPA2024 is NOW OPEN

Abstract Submission for the 27th Annual BOPA Conference in 2024 is now OPEN   Delegates are invited to present results of their clinical and technical work as a poster with…

Read article
By BOPA Research Subcommittee on 15th April 2024

Survey: Service Evaluation on Carboplatin Variation in UK

We invite members to complete this service evaluation to understand national variations in carboplatin dosing for adult patients receiving SACTs. We are looking at whether we can standardise carboplatin protocols…

Read article